Patent · US Active

Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor

US9474754B2 · kind B2 · utility

7Cited by

0References

16Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Giordano Caponigro · Salt Lake City, US
Darrin Stuart · Edmonton, CA
Laure Moutouh-De Parseval · Basel, CH

Key dates

Filing date	Aug 5, 2013
Grant date	Oct 25, 2016
Priority date	—
Expiry date	Aug 5, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A pharmaceutical combination comprising (a) a B-Raf inhibitor, (b) a EGFR inhibitor and, optionally, (c) a PI3K inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.